https://assets.capyfin.com/instruments/678fdc13234e27009c5d585c.png avatar
Baxter
🇺🇸 NYSE:BAX
View Company
OverviewEarningsDividends
•
Mar 31, 2021

Baxter Q1 2021 Earnings Report

Reported a 5% increase in first-quarter revenue and a decline in both U.S. GAAP EPS and Adjusted EPS.

Key Takeaways

Baxter International Inc. reported a 5% increase in first-quarter revenue, driven by Acute Therapies and BioPharma Solutions. The company's U.S. GAAP earnings per share (EPS) declined 9%, and adjusted EPS decreased by 7%. Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis.

First-quarter revenue increased 5% on a reported basis.

U.S. GAAP earnings per share (EPS) declined 9%.

Adjusted EPS declined 7%.

Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis.

Total Revenue
$2.95B
Previous year: $2.8B
+5.1%
EPS
$0.76
Previous year: $0.82
-7.3%
Gross Profit
$1.15B
Previous year: $1.16B
-1.5%
Cash and Equivalents
$3.18B
Previous year: $4.11B
-22.6%
Total Assets
$19.5B
Previous year: $19.1B
+2.0%

Baxter

Baxter

Baxter Revenue by Geographic Location

Forward Guidance

Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis. The company expects U.S. GAAP earnings of $2.85 to $2.93 per diluted share and adjusted earnings of $3.47 to $3.55 per diluted share.

Positive Outlook

  • Full-year 2021 sales growth of 8% to 9% on a reported basis.
  • Full-year 2021 sales growth of 5% to 6% on a constant currency basis.
  • Full-year 2021 sales growth of 4% to 5% on an operational basis.
  • Full-year U.S. GAAP earnings of $2.85 to $2.93 per diluted share.
  • Full-year adjusted earnings of $3.47 to $3.55 per diluted share.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Baxter